Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of the company’s capacity into the biotech field, and its readiness to increase collaboration with both pharma companies and Cofepris to further strengthen Mexico’s healthcare eco-system.
DEFI Latina has been steadily developing and consolidating its leadership position as the partner of choice of both the healthcare industry and Cofepris. In this sense, you notably received in January 2016 the certification to review biotech treatments’ approval dossiers on behalf of Cofepris. To what extent does this certification stand as an important milestone for DEFI?
"Although the Mexican biotech market is still maturing, we undoubtedly notice a strong trend in bringing to the market an increasing number of therapies targeting diseases with a developing national prevalence, such as diabetes, cardiovascular diseases and cancer - and most of these therapies are biotech treatments."
